Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Li, Lulu ^a,b   Zhang, Minli ^a   Su, Fuxiang ^a   Li, Yang ^a   Shen, Yali ^a   Shen, Jie ^a   Zhang, Daqing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute coronary syndrome; Combination therapy; Diabetes; Ezetimibe; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; DISEASE CONTROL; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT SAFETY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHINA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; C-REACTIVE PROTEIN; CHINA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 84924074175     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0004-7     Document Type: Article

References (22)

1. Goldfine Allison B, Beckman Joshua A. Life and death in Denmark: lessons about diabetes and coronary heart disease. Circulation. 2008;117:1914-7.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
3. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31:236-44.
4. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, et al. 2014 AHA/ACC Guideline for the Management of patients with non-ST-elevation acute coronary syndrome. J Am Coll Cardiol. 2014;S0735-1097(14):06279-2.
5. Zhao S, Wang Y, Yiming M, Yu B, Ye P, Yan X, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DY Slipidemia International Study (DYSIS). Atherosclerosis. 2014;235:463-9.
6. Rocco Michael BR. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med. 2012;79:883-93.
7. HPS2-THRIVE Collaborative Group. HPS2-THRIVER randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-91.
8. Neal Ryan C, Jones Peter H. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manage. 2006;2:31-8.
9. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009-26.
10. Necati D, Mustafa Y, Ilgin K. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation. 2007;30:230-5.
11. Nomura M, Ishii H, Kawakami A, Kajinami A, Yoshida M. Inhibition of hepatic Neiman-pick C1-Like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab. 2009;297:E1030-8.
12. Joint committee for developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:390-419.
13. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353:1124-34.
14. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-45.
15. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
16. Deharo P, Pankert M, Quilici J, Grosdidier C, Verdier V, Bonnet G, et al. Safety and effectiveness of the association ezetimibe-statin (E-S) versus highdose rosuvastatin after acute coronary syndrome: the safe-ES study. Ann Cardiol Angeiol. 2014;63:222-7.
17. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-8.
18. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest. 2007;37:357-63.
19. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Ciculation. 2003;107:2409-15.
20. Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013;231:8-14.
21. Undas A, Machnik A, Potaczek DP, Wypasek E, Zmudka K, Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharma. 2011;58:167-72.
22. Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomized controlled study. Eur J Clin Invest. 2012;42:1287-94.